|
|
|
|
BioTrends Provides Insight into the Global Renal Anemia Market with the Release of Three Nephrology TreatmentT
EXTON, Pa., Jan.6 /PRNewswire/ -- BioTrends Research Group, Inc. is pleased to announce the availability of its TreatmentTrends: US Nephrology, EU Nephrology, and Canadian Nephrology publications. The reports are based on responses to online surveys...
|
|
|
Amgen wins recombinant erythropoietin patent dispute against Roche
Amgen announced that the United States (US) District Court in Boston has entered final judgment and a permanent injunction against Roche prohibiting Roche from infringing Amgen's patents on recombinant erythropoietin (EPO), thus bringing the five-year patent...
|
|
|
Amgen wins anemia drug patent dispute with Roche
-0400 (Reuters Health) * Roche admits Mircera infringes Amgen patents * Under deal, Roche can sell Mircera in U.S.in mid-2014 * No financial payments involved in settlement NEW YORK (Reuters) - A U.S. court ruled that Roche Holding's anemia...
|
|
|
Amgen Resolves EPO Patent Dispute With Roche
Roche Admits Infringement And Validity Of Amgen's EPO Patents; Court Enters Permanent Injunction; Amgen Allows Roche's MIRCERA Onto U.S.Market In Mid-2014 THOUSAND OAKS, Calif., Dec. 22 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) announced today...
|
|
|
Amgen Resolves EPO Patent Dispute With Roche
THOUSAND OAKS, Calif., Dec.22 /PRNewswire-FirstCall/ -- Amgen announced today that the United States (U.S.) District Court in Boston has entered final judgment and a permanent injunction against Roche prohibiting Roche from infringing Amgen's patents on...
|
